Citigroup’s Filana Therapeutics FLNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $34 | Sell |
20
-42
| -68% | -$86 | ﹤0.01% | 5672 |
|
|
2025
Q4 | $123 | Sell |
62
-2,374
| -97% | -$7.6K | ﹤0.01% | 5658 |
|
|
2025
Q3 | $7.09K | Sell |
2,436
-18,603
| -88% | -$42.8K | ﹤0.01% | 5118 |
|
|
2025
Q2 | $38.1K | Sell |
21,039
-9,855
| -32% | -$17.5K | ﹤0.01% | 4895 |
|
|
2025
Q1 | $46.3K | Sell |
30,894
-8,260
| -21% | -$20.8K | ﹤0.01% | 4886 |
|
|
2024
Q4 | $92.4K | Sell |
39,154
-3,105
| -7% | -$54.5K | ﹤0.01% | 4882 |
|
|
2024
Q3 | $1.24M | Buy |
42,259
+23,922
| +130% | +$551K | ﹤0.01% | 3084 |
|
|
2024
Q2 | $226K | Sell |
18,337
-3,487
| -16% | -$73.5K | ﹤0.01% | 3820 |
|
|
2024
Q1 | $443K | Buy |
21,824
+963
| +5% | +$22.2K | ﹤0.01% | 3659 |
|
|
2023
Q4 | $470K | Buy |
20,861
+6,993
| +50% | +$148K | ﹤0.01% | 3443 |
|
|
2023
Q3 | $231K | Sell |
13,868
-9,513
| -41% | -$189K | ﹤0.01% | 3586 |
|
|
2023
Q2 | $573K | Buy |
23,381
+7,999
| +52% | +$193K | ﹤0.01% | 3275 |
|
|
2023
Q1 | $371K | Buy |
15,382
+2,051
| +15% | +$56.8K | ﹤0.01% | 3335 |
|
|
2022
Q4 | $394K | Sell |
13,331
-1,468
| -10% | -$52.8K | ﹤0.01% | 3330 |
|
|
2022
Q3 | $619K | Sell |
14,799
-4,487
| -23% | -$121K | ﹤0.01% | 3084 |
|
|
2022
Q2 | $543K | Buy |
19,286
+3,495
| +22% | +$88.3K | ﹤0.01% | 3155 |
|
|
2022
Q1 | $587K | Sell |
15,791
-6,990
| -31% | -$296K | ﹤0.01% | 3401 |
|
|
2021
Q4 | $996K | Sell |
22,781
-16,120
| -41% | -$845K | ﹤0.01% | 3264 |
|
|
2021
Q3 | $2.42M | Buy |
38,901
+29,391
| +309% | +$2.45M | ﹤0.01% | 2384 |
|
|
2021
Q2 | $813K | Buy |
9,510
+3,451
| +57% | +$185K | ﹤0.01% | 3378 |
|
|
2021
Q1 | $272K | Sell |
6,059
-253
| -4% | -$9.95K | ﹤0.01% | 3832 |
|
|
2020
Q4 | $43K | Buy |
6,312
+5,198
| +467% | +$46.4K | ﹤0.01% | 6150 |
|
|
2020
Q3 | $13K | Sell |
1,114
-2,096
| -65% | -$9.45K | ﹤0.01% | 6469 |
|
|
2020
Q2 | $10K | Buy |
3,210
+2,910
| +970% | +$13.2K | ﹤0.01% | 7061 |
|
|
2020
Q1 | $1K | Buy |
+300
| New | +$1.99K | ﹤0.01% | 7510 |
|
|
2016
Q3 | – | Sell |
-200
| Closed | -$3K | – | 7171 |
|
|
2016
Q2 | $3K | Hold |
200
| – | – | ﹤0.01% | 6878 |
|
|
2016
Q1 | $3K | Hold |
200
| – | – | ﹤0.01% | 7141 |
|
|
2015
Q4 | $2K | Sell |
200
-2,143
| -91% | -$28.4K | ﹤0.01% | 7276 |
|
|
2015
Q3 | $30K | Sell |
2,343
-66
| -3% | -$833 | ﹤0.01% | 5754 |
|
|
2015
Q2 | $29K | Sell |
2,409
-300
| -11% | -$4.11K | ﹤0.01% | 5892 |
|
|
2015
Q1 | $36K | Sell |
2,709
-633
| -19% | -$8.54K | ﹤0.01% | 5733 |
|
|
2014
Q4 | $47K | Buy |
3,342
+714
| +27% | +$12.4K | ﹤0.01% | 5733 |
|
|
2014
Q3 | $72K | Buy |
2,628
+2,079
| +379% | +$63.2K | ﹤0.01% | 5031 |
|
|
2014
Q2 | $22K | Buy |
549
+220
| +67% | +$8.14K | ﹤0.01% | 5764 |
|
|
2014
Q1 | $13K | Buy |
329
+311
| +1,728% | +$11K | ﹤0.01% | 6239 |
|
|
2013
Q4 | $1K | Sell |
18
-1,225
| -99% | -$32.5K | ﹤0.01% | 6875 |
|
|
2013
Q3 | $24K | Buy |
1,243
+1,234
| +13,711% | +$21.6K | ﹤0.01% | 5801 |
|
|
2013
Q2 | $0 | Buy |
+9
| New | +$190 | ﹤0.01% | 6786 |
|
Other funds holding FLNA
VCM
GC
Citigroup's FLNA Position: Q1 2026 in Review
Citigroup reduced its Filana Therapeutics (FLNA) stake by 68% in Q1 2026, selling an estimated $86 and leaving 20 shares worth $34. The position accounts for ﹤0.01% of the portfolio, ranked #5672.
Citigroup first reported a position in FLNA in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.42M in Q3 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.
- Citigroup held 20 shares of Filana Therapeutics worth $34 as of Q1 2026.
- Citigroup sold 42 Filana Therapeutics shares in Q1 2026, an estimated $86.
- Filana Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5672 holding.
- Citigroup first reported a position in Filana Therapeutics in Q2 2013 and has held it in 38 quarters since.
- Citigroup's Filana Therapeutics position peaked at $2.42M in Q3 2021.
- 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.